These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17764645)

  • 1. Using prandial insulin to achieve glycemic control in type 2 diabetes.
    Dailey GE
    J Fam Pract; 2007 Sep; 56(9):735-42. PubMed ID: 17764645
    [No Abstract]   [Full Text] [Related]  

  • 2. Exenatide for once-weekly administration.
    Drug Ther Bull; 2012 Jul; 50(7):78-80. PubMed ID: 22789767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longacting exenatide in diabetes: DURATION-3.
    Misra A; Joshi S
    Lancet; 2010 Jun; 375(9733):2198-9. PubMed ID: 20609957
    [No Abstract]   [Full Text] [Related]  

  • 4. Individualised incretin-based treatment for type 2 diabetes.
    Nauck MA; Meier JJ
    Lancet; 2010 Aug; 376(9739):393-4. PubMed ID: 20580425
    [No Abstract]   [Full Text] [Related]  

  • 5. Physiologic insulin replacement in type 2 diabetes: optimizing postprandial glucose control.
    Robertson C
    Diabetes Educ; 2006; 32(3):423-32. PubMed ID: 16772658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes drug update: how 4 new options stack up.
    Taylor JR; Campbell KM
    J Fam Pract; 2007 Mar; 56(3):207-15. PubMed ID: 17343811
    [No Abstract]   [Full Text] [Related]  

  • 7. Hormone copycats.
    Gebel E
    Diabetes Forecast; 2012 Jun; 65(6):36, 38-9. PubMed ID: 22737769
    [No Abstract]   [Full Text] [Related]  

  • 8. [Reply on new drugs against type 2 diabetes: important to gain experience and knowledge].
    Sjöholm A; Agardh CD; Brismar K; Efendic S; Eliasson B; Eriksson JW; Frid A; Groop L; Holmgren J; Ridderstråle M; Smith U
    Lakartidningen; 2008 Apr 23-May 6; 105(17-18):1310, 1312. PubMed ID: 18561535
    [No Abstract]   [Full Text] [Related]  

  • 9. Challenges and strategies for moving patients to injectable medications.
    Siminerio L
    Diabetes Educ; 2006; 32 Suppl 2():82S-90S. PubMed ID: 16554432
    [No Abstract]   [Full Text] [Related]  

  • 10. [Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].
    MMW Fortschr Med; 2009 May; 151(19):50. PubMed ID: 19827447
    [No Abstract]   [Full Text] [Related]  

  • 11. The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin.
    Shaefer CF; Anderson J
    Postgrad Med; 2016 Jan; 128(1):137-44. PubMed ID: 26548422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
    Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
    Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows.
    Cohen D
    BMJ; 2013 Feb; 346():f1304. PubMed ID: 23447395
    [No Abstract]   [Full Text] [Related]  

  • 14. [Primary combined oral antidiabetic therapy in type-2 diabetes mellitus].
    Winkler G; Baranyi E
    Orv Hetil; 2002 Oct; 143(43):2441-7. PubMed ID: 12455146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achieving fasting and postprandial blood glucose control in type 2 diabetes.
    Robertson D
    Br J Hosp Med (Lond); 2006 Oct; 67(10):518-22. PubMed ID: 17069120
    [No Abstract]   [Full Text] [Related]  

  • 16. [Thanks to fast acting insulin analogs, diabetes therapy without hourly schedule].
    MMW Fortschr Med; 2002 Nov; 144(46):71. PubMed ID: 12534091
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lispro mixed insulins in type 2 diabetes. Preventing postprandial insulin rise].
    MMW Fortschr Med; 2000 Jul; 142(28-29):58-9. PubMed ID: 10959169
    [No Abstract]   [Full Text] [Related]  

  • 18. Distinguishing among incretin-based therapies. Introduction.
    Campbell RK; Cobble ME; Reid TS; Shomali ME
    J Fam Pract; 2010 Sep; 59(9 Suppl 1):S3-4. PubMed ID: 20824238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
    Madsbad S; Krarup T; Deacon CF; Holst JJ
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):491-9. PubMed ID: 18542012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the role of incretin mimetic therapy in the management of type 2 diabetes.
    Unger J; Nadeau DA
    J Fam Pract; 2007 Dec; 56(12 Suppl New):S4-S10. PubMed ID: 18664341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.